Browse the corpus

©2013 UpToDate ® Print Email Ann Arbor staging classification for Hodgkin and non-Hodgkin lymphomas Stage I Involvement of a single lymph node region (I) or of a single extralymphatic organ or site (IE)* Stage II Involvement of two or more lymph node regions or lymphatic structures on the same side of the diaphragm alone (II) or with involvement of limited, contiguous extralymphatic organ or tissue (IIE) Stage III Involvement of lymph node regions on both sides of the diaphragm (III), which may include the spleen (IIIS) or limited, contiguous extralymphatic organ or site (IIIE) or both (IIIES) Stage IV Diffuse or disseminated foci of involvement of one or more extralymphatic organs or tissues, with or without associated lymphatic involvement All cases are subclassified to indicate the absence (A) or presence (B) of the systemic ("B") symptoms of significant unexplained fever (>38 degrees C), night sweats, or unexplained weight loss exceeding 10 percent of body weight during the six months prior to diagnosis. Clinical stage refers to the extent of disease determined by diagnostic tests following a single diagnostic biopsy. If a second biopsy of any kind is obtained, even if negative, the term pathologic stage is used. * The designation "E" generally refers to extranodal contiguous extension (ie, proximal or contiguous extranodal disease) that can be encompassed within an irradiation field appropriate for nodal disease of the same anatomic extent. A single extralymphatic site as the only site of disease should be classified as IE, rather than stage IV. Adapted from Carbone PP, et al. Cancer Res 1971; 31:1860 and Lister TA, et al. J Clin Oncol 1989; 7:1630.